Analysis of intrahepatic sarcomatoid cholangiocarcinoma: Experience from 11 cases within 17 years

Table 5 Immunohistochemistry of the patients with intrahepatic sarcomatoid cholangiocarcinoma

Case	Specimen	Positive IHC results	Negative IHC results
1	Needle biopsy	CK19, vimentin	HSA, CD10
2	Needle biopsy	CK, vimentin, CEA, AFP	CK7, CK19, HSA, c-kit, CD117
3	Needle biopsy	CK, CK19, vimentin	CK8, Desmin, EMA, CEA, c-kit, S-100
4	Needle biopsy	CK, CK8, CK19, vimentin, CEA, EMA	HSA, AFP, TTF-1
5	Needle biopsy	CK, CK8, CK19, vimentin, SMA	HSA, CD5, CD68, HMW-CK
6	Needle biopsy	CK7, CK8, CK19, vimentin, CEA	HSA
7	Needle biopsy	CK7, CK8, CK19, vimentin, CD34	HSA, CEA, HMW-CK
8	Needle biopsy	CK19, vimentin, CEA, p53	CD31, CD34
9	Needle biopsy	CK19, vimentin, CEA	CK7, Desmin, HSA, SMA, c-kit, S-100
10	Needle biopsy	CK, CK19, vimentin, CEA	HSA, CD31
11	Needle biopsy	CK7, CK19, vimentin, MUC1	HSA, CD10

AFP: Alpha-fetoprotein; CD: Cluster of differentiation; CEA: Carcinoembryonic antigen; CK: Cytokeratin; EMA: Epithelial membrane antigen; HMW-CK: High molecular weight cytokeratin; HSA: Hepatocyte specific antigen; IHC: Immunohistochemistry; MUC1: Human mucin-1; SMA: Smooth muscle actin; TTF-1: Thyroid transcription factor-1.